Anzeige
Mehr »
Login
Sonntag, 26.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Der SILBER-STURM kommt - wie diese unterbewertete Firma die Investmentwelt aufmischt und Milliardenwerte hebt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AFXS | ISIN: US2210151005 | Ticker-Symbol: C17
Tradegate
23.05.24
10:30 Uhr
1,916 Euro
+0,012
+0,63 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CORVUS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
CORVUS PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,8401,96025.05.
1,8381,96824.05.

Aktuelle News zur CORVUS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.05.Corvus Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
07.05.Corvus Pharmaceuticals, Inc. - 10-Q, Quarterly Report1
07.05.Earnings call: Corvus Pharmaceuticals Q1 2024 financial results and trials update2
06.05.Corvus Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary2
06.05.Corvus Pharmaceuticals GAAP EPS of -$0.12 beats by $0.013
06.05.Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results93Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024 Soquelitinib Registration Phase 3 Trial in Peripheral T Cell...
► Artikel lesen
06.05.CRVS, CTMX and NRXP are among premarket gainers14
03.05.Corvus Pharmaceuticals Q1 2024 Earnings Preview1
02.05.Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering3
01.05.Corvus Pharmaceuticals, Inc. - 8-K, Current Report1
09.04.Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis82Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company's selective ITK inhibitor Corvus anticipates releasing initial clinical data from...
► Artikel lesen
20.03.Earnings call: Corvus Pharmaceuticals outlines trials and financials2
19.03.Corvus Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary3
19.03.Corvus Pharmaceuticals GAAP EPS of -$0.14 misses by $0.012
19.03.Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results144Soquelitinib advancing towards initial enrollment for registrational Phase 3 clinical trial for PTCL and randomized Phase 1 clinical trial for atopic dermatitis Orphan drug designation and new interim...
► Artikel lesen
19.03.Corvus Pharmaceuticals, Inc. - 8-K, Current Report2
12.02.Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases243BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib...
► Artikel lesen
12.02.Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up2
09.02.Corvus Pharma up as FDA grants orphan drug tag to blood cancer therapy1
23.01.Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell4
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1